YH-36400
YH-36400 is an orally bioavailable inhibitor of HIF-1α and HIF-2α. YH-36400 disrupts the dimerization of HIF-1α and HIF-1β and triggers proteasomal degradation, thereby inhibiting the transcriptional activities of HIF-1 and HIF-2. YH-36400 reduces the expression of PD-L1 and CD73, reprograms the tumor immune microenvironment, inhibits angiogenesis, and can be used in combination with immune checkpoint blockade therapy. YH-36400 is applicable to research related to breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, and head and neck squamous cell carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3112733-78-2
- Formule: C27H38N6S2
- Masse moléculaire:510.76
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
SS1.21 is as effective as oxaliplatin at inhibiting human colorectal tumor growth in nude mice, and combination therapy enhances efficacy without increased toxicity relative to oxaliplatin alone[1].
SS1.21 inhibits mouse colorectal tumor growth in immunocompetent mice by reducing HIF-1α protein levels and impairing tumor vascularization without causing detectable toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 3112733-78-2
-
Masse moléculaire 510.76
-
Formule C27H38N6S2
-
SMILES
S=C(N1CCC(CCCC2CCN(C(NCC3=CC=NC=C3)=S)CC2)CC1)NCC4=CC=NC=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)